Latest news with #SynoGraph
The Market Online
02-07-2025
- Business
- The Market Online
Onco-Innovations reveals new study on global applicability of lung cancer clinical trials
Onco-Innovations (CBOE CA:ONCO) stated that the co-founders of its wholly-owned subsidiary, Inka Health Corp., have authored an intriguing new study The study addresses a critical challenge in oncology research: how to ensure that clinical trial results are relevant and applicable to the diverse patient populations encountered in everyday clinical practice across different countries and healthcare systems Using advanced modeling techniques, the study demonstrated that trial outcomes could be translated to real-world settings with pinpoint accuracy—within less than one percent error over a 30-month period Onco-Innovations (CBOE CA:ONCO) last traded at C$2.23 This content has been prepared in collaboration with Onco-Innovations Ltd. , a third-party issuer, and is intended for informational purposes only. Onco-Innovations (CBOE CA:ONCO) stated that the co-founders of its wholly-owned subsidiary, Inka Health Corp., have authored an intriguing new study titled Global Transportability of Clinical Trial Outcomes to Real-World Lung Cancer Populations: A Case Study using Lung-MAP S1400I , published in medRxiv in June 2025. The study addresses a critical challenge in oncology research: how to ensure that clinical trial results are relevant and applicable to the diverse patient populations encountered in everyday clinical practice across different countries and healthcare systems. Using advanced modeling techniques, the study demonstrated that trial outcomes could be translated to real-world settings with pinpoint accuracy—within less than one percent error over a 30-month period. Implications for global drug development The findings have significant implications for the future of clinical trial design and drug development. By simulating patient outcomes in advance, researchers can optimize trial parameters and better define target populations, reducing risk and accelerating development timelines. These methodologies are foundational to SynoGraph, Inka Health's next-generation causal AI platform, which aims to revolutionize drug development through globally applicable, real-world analytics. Study highlights The research focused on the Lung-MAP S1400I trial, a leading randomized study for advanced non-small cell lung cancer (NSCLC). It evaluated whether trial results could accurately predict outcomes for real-world patients in the U.S., Germany, and France—many of whom would not have qualified for the original trial due to age, comorbidities, or other factors. Key findings include: Enhanced predictive accuracy : By incorporating external clinical knowledge, the model achieved an average discrepancy of just 0.27 months (8.2 days) between predicted and actual survival outcomes. : By incorporating external clinical knowledge, the model achieved an average discrepancy of just 0.27 months (8.2 days) between predicted and actual survival outcomes. Broader applicability : The approach significantly improved the alignment of trial results with real-world outcomes, offering a scalable solution for global oncology research. : The approach significantly improved the alignment of trial results with real-world outcomes, offering a scalable solution for global oncology research. Regulatory relevance: The study supports growing demands from regulators, payers, and clinicians for evidence that reflects real-world patient experiences. Leadership insights Among the study's co-authors is Dr. Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute. A globally recognized leader in oncology, Dr. Subbiah has led over 100 early-phase clinical trials and contributed to multiple FDA and EMA approvals, including tissue-agnostic therapies targeting BRAF and RET genetic alterations. He has authored more than 400 peer-reviewed publications in top-tier journals such as The New England Journal of Medicine , Nature Medicine , and JAMA Oncology . 'The ability to model outcomes for patient groups who wouldn't typically be included in clinical trials is not just a technical achievement-it's a clinical and strategic one,' he said in a news release. 'It opens the door to faster trial design, smarter expansion decisions, and better evidence for patients who are often overlooked. These kinds of tools will be essential as we push toward more globally inclusive and data-driven drug development.' Onco-Innovations Ltd. studies cancer research and treatment, specializing in oncology. Onco-Innovations (CBOE CA:ONCO) last traded at C$2.23. Join the discussion: Find out what everybody's saying about this stock on the Onco-Innovations Bullboard, and check out the rest of Stockhouse's stock forums and message boards. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein.
Associated Press
07-02-2025
- Business
- Associated Press
Onco-Innovations Announces Expression of Interest Between Inka Health and Global Data Leader, Quantify Research
VANCOUVER, BC / ACCESS Newswire / February 6, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN:A3EKSZ) ('Onco' or the 'Company') is pleased to announce that its wholly-owned subsidiary, Inka Health Corp. ('Inka Health') has entered into an Expression of Interest (EOI) with Quantify Research ('Quantify'), a leading global provider of healthcare data analytics and real-world evidence solutions. This EOI establishes a framework for potential collaboration between the two entities to explore synergies in advanced data analytics and oncology research, with a particular focus on leveraging AI-driven predictive modelling to enhance cancer treatment insights. Quantify Research is a recognized leader in healthcare data analytics, specializing in health economics, outcomes research, and real-world evidence. With a decade of expertise in leveraging large Nordic and European healthcare data, Quantify provides critical insights to pharmaceutical companies, regulatory bodies, and healthcare institutions worldwide.1 Quantify, possessing unique access to high-quality real-world data (26 million+ patients with high coverage and lifetime follow up2) and expertise in RWD analytics, has expressed interest in collaborating with Inka Health to support the development of SynoGraph™ - Inka's proprietary platform designed to enhance precision medicine through causal graphical models parameterized in part with real-world data (RWD) - by providing analytical contributions and expertise in real-world data insights, including AI-powered predictive analytics to improve oncology treatment strategies. Under the terms of the EOI, Inka Health and Quantify Research intend to explore opportunities to collaborate on data-driven research initiatives, particularly supporting the development of SynoGraph™. Quantify Research has expressed interest in assisting Inka Health with refining, parameterizing, and validating SynoGraph™ models by providing access to a controlled environment with real-world data analytics, including structured data from electronic health records (EHR), claims data, genomics, imaging, and other relevant clinical metrics. All data access and processing will adhere to strict privacy and security measures to ensure compliance with applicable regulatory requirements. 'This Expression of Interest with Quantify Research is a pivotal step in exploring the integration of advanced real-world data analytics with our AI-driven SynoGraph platform. By combining our strengths, we aim to enhance precision medicine approaches in oncology and improve patient outcomes through data-driven insights,' stated Paul Arora, CEO of Inka Health. The EOI represents a strategic step for Onco-Innovations, towards advancing its mission of transforming cancer treatment research and drug development. By leveraging Quantify Research's expertise in real-world data analytics, Onco's wholly-owned subsidiary, Inka Health can work towards enhancing the development of its SynoGraph platform, with the aim of enabling more precise modelling and data-driven insights. Onco is actively exploring how to synergize SynoGraph's advanced analytical capabilities to support Onco's goal of refining oncology treatment strategies, identifying key biomarkers, and optimizing clinical trial designs. 'Aligning with Quantify Research supports our vision of leveraging AI and real-world data to drive innovation in oncology research,' said Thomas O'Shaughnessy, CEO of Onco-Innovations. About Onco-Innovations Limited Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The Company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer. ON BEHALF OF ONCO-INNOVATIONS LIMITED, 'Thomas O'Shaughnessy' Chief Executive Officer For more information, please contact: Thomas O'Shaughnessy Chief Executive Officer Tel:+ 1 888 261 8055 The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release. Forward-Looking Statements Caution. This news release may contain forward-looking statements, including in relation to the EOI, the ability of the Company to realize synergies through its acquisition of Inka, the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as 'will', 'may', 'potential', 'should', 'anticipate', 'expects' and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements, including as a result of there being no agreement or arrangement with Quantify beyond the EOI, or the failure of the Company to realize on the synergies and benefits expected from its acquisition of Inka. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law. 1
